文献速递肥胖与代谢综合征糖尿病

二甲双胍联合饮食运动建议对超重或肥胖孕妇的效果:GRoW随机双盲安慰剂对照试验

Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-12-04

GRoW试验在澳大利亚三个产科单位纳入524名孕10-20周、BMI≥25 kg/m2的孕妇,随机接受二甲双胍(最大2000 mg/日)或安慰剂,均接受饮食运动干预。

要点

  • 二甲双胍未减少巨大儿(出生体重>4000 g)发生率。
  • 二甲双胍降低每周 gestational weight gain,更多孕妇增重低于推荐。
  • 妊娠及出生结局、饮食运动、生活质量与情绪健康无显著差异。

核心结论

  • 对于超重或肥胖孕妇,孕10-20周起在饮食运动建议基础上加用二甲双胍未改善妊娠和出生结局。

研究设计与样本

  • GRoW为多中心、随机、双盲、安慰剂对照试验,在澳大利亚阿德莱德三个公立产科单位招募孕10-20周、BMI≥25 kg/m2的孕妇。
  • 524名孕妇随机分配接受二甲双胍(最大2000 mg/日)或匹配安慰剂,所有孕妇均接受饮食运动干预。
  • 514名纳入意向性分析(二甲双胍组256名,安慰剂组258名)。

主要发现

  • 总 gestational weight gain、妊娠及出生结局、饮食运动、生活质量与情绪健康无显著差异。
  • 副作用报告率:二甲双胍组76%(159/208),安慰剂组73%(144/196),包括恶心、腹泻和呕吐。

关键数值与推荐

  • 二甲双胍最大剂量2000 mg/日,从孕10-20周开始使用。
  • 主要结局为出生体重>4000 g的婴儿比例。
  • gestational weight gain低于推荐的定义未在摘要中报告。

临床怎么用

  • 对于超重或肥胖孕妇,在饮食运动建议基础上加用二甲双胍不应以改善妊娠和出生结局为目的。
  • 二甲双胍可轻度减少每周 gestational weight gain,但临床意义需结合个体情况评估。

局限性

  • 摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal overweight and obesity are associated with well recognised pregnancy complications. Antenatal dietary and lifestyle interventions have a modest effect on gestational weight gain without affecting pregnancy outcomes. We aimed to assess the effects on maternal and infant outcomes of antenatal metformin given in addition to dietary and lifestyle advice among overweight and obese pregnant women. METHODS: GRoW was a multicentre, randomised, double-blind, placebo-controlled trial in which pregnant women at 10-20 weeks' gestation with a BMI of 25 kg/m2 or higher were recruited from three public maternity units in Adelaide, SA, Australia. Women were randomly assigned (1:1) via a computer-generated schedule to receive either metformin (to a maximum dose of 2000 mg per day) or matching placebo. Participants, their antenatal care providers, and research staff (including outcome assessors) were masked to treatment allocation. All women received an antenatal dietary and lifestyle intervention. The primary outcome was the proportion of infants with birthweight greater than 4000 g. Secondary outcomes included measures of maternal weight gain, maternal diet and physical activity, maternal pregnancy and birth outcomes, maternal quality of life and emotional wellbeing, and infant birth outcomes. Outcomes were analysed on an intention-to-treat basis (including all randomly assigned women who did not withdraw consent to use their data, and who did not have a miscarriage or termination of pregnancy before 20 weeks' gestation, or a stillbirth). The trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12612001277831. FINDINGS: Of 524 women who were randomly assigned between May, 28 2013 and April 26, 2016, 514 were included in outcome analyses (256 in the metformin group and 258 in the placebo group). Median gestational age at trial entry was 16·29 weeks (IQR 14·43-18·00) and median BMI was 32·32 kg/m2 (28·90-37·10); 167 (32%) participants were overweight and 347 (68%) were obese. There was no significant difference in the proportion of infants with birthweight greater than 4000 g (40 [16%] with metformin vs 37 [14%] with placebo; adjusted risk ratio [aRR] 0·97, 95% CI 0·65 to 1·47; p=0·899). Women receiving metformin had lower average weekly gestational weight gain (adjusted mean difference -0·08 kg, 95% CI -0·14 to -0·02; p=0·007) and were more likely to have gestational weight gain below recommendations (aRR 1·46, 95% CI 1·10 to 1·94; p=0·008). Total gestational weight gain, pregnancy and birth outcomes, maternal diet and physical activity, and maternal quality of life and emotional wellbeing did not differ significantly between groups. Similar numbers of women in both treatment groups (76% [159/208] in the metformin group and 73% [144/196] in the placebo group) reported side-effects including nausea, diarrhoea, and vomiting. Two stillbirths (placebo group) and one neonatal death (metformin group) occurred; none of the perinatal deaths were determined to be attributable to participation in the trial. INTERPRETATION: For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes. FUNDING: Australian National Health and Medical Research Council.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Dodd JM, Louise J, Deussen AR, et al. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018. PMID: 30528218. doi:10.1016/S2213-8587(18)30310-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。